ClinicalTrials.gov
ClinicalTrials.gov Menu

Polish Mother and Child Cohort Study (REPRO_PL) - Follow up of the Children. (REPRO_PL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01861548
Recruitment Status : Completed
First Posted : May 23, 2013
Last Update Posted : May 23, 2013
Sponsor:
Information provided by (Responsible Party):
Iwona Stelmach, Medical Universtity of Lodz

Brief Summary:

The Polish Mother and Child Cohort is multicentre prospective study on different exposures.

Prospective cohort study design enables identification of exposures that may influence pregnancy outcome and chil-dren's health, verification of such exposures by biomarker measurements and notification of any changes in exposure levels.

The aim of the study is to evaluate the impact of exposure to different environmental factors during pregnancy and after birth on pregnancy outcome and children's health. Specific research hypotheses refer to the role of heavy metals, exposure to polycyclic aromatic hydrocar-bons (PAHs) and environmental tobacco smoke (ETS) in the aetiology of intrauterine growth retardation (IUGR), preterm delivery (PD) and the risk of respiratory diseases, allergy and poor mental and physical development. It is also intended to explain the role of oxidative stress and nutritional status of the pregnant women. The impact of occupational exposures and stressful situations on pregnancy outcome will be evaluated from question-naire data.

The results of the study will help to determine levels of child prenatal and postnatal exposure in several areas of Poland and their im-pact on course and outcome of pregnancy and children's health.

This protocol concerns the children that are followed-up from birth to the age of 2 years to determine long term effects of pre- and postnatal environmental exposures.


Condition or disease
Asthma Atopic Dermatitis Food Allergy Wheezing

  Show Detailed Description

Study Type : Observational
Actual Enrollment : 479 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Polish Mother and Child Cohort Study (REPRO_PL).Follow up of the Children.
Study Start Date : January 2007
Actual Primary Completion Date : May 2013
Actual Study Completion Date : May 2013

Resource links provided by the National Library of Medicine


Group/Cohort
Children (up to 24 months after birth)
Investigators include into the study children delivered from women observed starting from between 8-12 weeks of single pregnancy, not assisted with reproductive technology, and not expected to be finished as spontaneous abor-tion. All women with the serious chronic diseases specified in study protocol such as diabetes, hypertension, nephrop-athy, epilepsy and cancer are excluded from the study. The same refers to suspicion of serious child malformations known to exist at the inclusion into the study.



Primary Outcome Measures :
  1. Exposure of children to Environmental tobacco smoke(ETS) [ Time Frame: Change from baseline of exposure of children to environmental tobacco smoke at 12 months ]
    Postnatal children exposure to ETS at 12, and 24 months after birth is assessed. From the children urine sample and saliva samples from mothers who will declare smoking abstinence are collected. The saliva and urine cotinine level is analysed using high performance liquid chromatography coupled with tandem mass spectrometry/positive electrospray ionization (LC-ESI+MS/MS) and isotope dilution.


Secondary Outcome Measures :
  1. Exposure of children to polycyclic aromatic hydrocarbons (PAH) [ Time Frame: Change from baseline of exposure of children to polycyclic aromatic hydrocarbons at 12 months ]
    The high performance liquid chromatography (HPLC) technique is used for the analysis of the level of 1-hydroksypyrene in urine as the biomarker of PAH exposure.

  2. Exposure to lead, cadmium, mercury in children. [ Time Frame: Change from baseline of exposure to lead, cadmium, mercury in children at 12 months. ]
    Blood and hair are collected for about 100 children. Total and inorganic mercury is analyzed using cold vapour atomic fluorescence spectrophotometry. The lead and cadmium concentrations in blood is determined by graphite-furnance atomic-absorption spectrometry.

  3. Exposure to indoor allergens, endotoxins and glucans in children. [ Time Frame: Change from baseline of exposure to indoor allergens, endotoxins and glucans in children at 12 months. ]
    The analyzis is covered approx. 50 family homes of children. The settled dust is collected from floors in leaving rooms and in children beds (mattresses and blankets). To determine allergens concentrations in dust samples, the commercially available enzymelinked immunosorbent assey (ELISA) kits ispplied according to the protocol.To determine endotoxins and (1→3)-β-D-glucans concentrations the LAL test will be applied. The questionnaire study is performed among parents in order to obtain the data about demographic factors and home conditions.

  4. Questionnaires conducted with mothers. [ Time Frame: Change from baseline of questionnaires scores at 12 months. ]
    Mothers of all children are interviewed. The questionnaires investigate the children's health and development, the nutrition of the small child and their contacts with other children. The smoking status of the parents and other potential sources of children's ETS exposure are identified. Information about proximity to heavy traffic is inquired. Additionally the information from the closets to his/her place of living air pollution monitoring station is collected. Exposure to other environmental factors including domestic animals, home dust, household cleaning agents and indoor used pesticides is evaluated by the questionnaire.

  5. Determination of the prevalence of the upper and lower respiratory tract infections, middle ear diseases and allergy among the child. [ Time Frame: Change from baseline of the prevalence of infections and allergies at 12 months ]
    The incidence of the upper and lower respiratory tract infections, middle ear diseases and symptoms of allergy among the child is identified based on the detailed interview with the mothers in 12 and 24 month after child birth. This interviews is conducted by paediatricians. For each child upper and lower respiratory tract infections (tonsillitis, laryngitis, bronchitis and pneumonia), as well as middle ear diseases and allergy to food and inhalant allergens is identified based on the review of their medical charts. The duration of each infection and disease, medications taken and hospitalization is identified. The current health status of the chid and child' anthropometry (high, weight) is preformed by pediatrician.

  6. Determination of the neurodevelopment of the children. [ Time Frame: Change from baseline of the neurodevelopment of the children at 12 months ]
    Bayley Scales of Infant Development (BSID-III) is used for assessment of child neurodevelopment. The tests is scheduled on 12 and/ 24 months of live and is conducted by psychologist or child development specialist. The test assesses five developmental areas of the child: cognitive, motor (fine and gross motor), language (receptive, expressive), social-emotional and adaptive behavior.


Biospecimen Retention:   Samples With DNA
blood, urine, hair, saliva


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 24 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Investigators include into the study children delivered from women observed starting from between 8-12 weeks of single pregnancy, not assisted with reproductive technology, and not expected to be finished as spontaneous abor-tion. All women with the serious chronic diseases specified in study protocol such as diabetes, hypertension, nephrop-athy, epilepsy and cancer are excluded from the study. The same refers to suspicion of serious child malformations known to exist at the inclusion into the study.
Criteria

Inclusion Criteria:

  • Investigators include into the study children delivered from women observed starting from between 8-12 weeks of single pregnancy, not assisted with reproductive technology, and not expected to be finished as spontaneous abor-tion. All women with the serious chronic diseases specified in study protocol such as diabetes, hypertension, nephrop-athy, epilepsy and cancer are excluded from the study. The same refers to suspicion of serious child malformations known to exist at the inclusion into the study.

Exclusion Criteria:

  • Serious child malformations known to exist at the inclusion into the study.
  • Children delivered from all women with the serious chronic diseases specified in study protocol such as diabetes, hypertension, nephrop-athy, epilepsy and cancer are excluded from the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01861548


Locations
Poland
Nofer Institute of Occupational Medicine, Department of Environmental Epidemiology
Lodz, Poland, 91-348
Department of Pediatrics and Allergy, Medical University of Lodz, N. Copernicus Hospital, Lodz, Poland
Lodz, Poland, 93-513
Sponsors and Collaborators
Medical Universtity of Lodz
Investigators
Principal Investigator: Iwona Stelmach, MD,PhD,Prof. Department of Pediatrics and Allergy, Medical University of Lodz, N. Copernicus Hospital, Lodz, Poland
Principal Investigator: Monika Kopka, MD Department of Pediatrics and Allergy, Medical University of Lodz, N. Copernicus Hospital, Lodz, Poland
Principal Investigator: Wojciech Hanke, MD,PhD,Prof. Nofer Institute of Occupational Medicine, Department of Environmental Epidemiology
Principal Investigator: Kinga Polanska, MD, PhD Nofer Institute of Occupational Medicine, Department of Environmental Epidemiology

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Iwona Stelmach, MD, PhD, Prof., Medical Universtity of Lodz
ClinicalTrials.gov Identifier: NCT01861548     History of Changes
Other Study ID Numbers: PBZ-MEiN-/8/2//2006
PNRF-218-AI-1/07 ( Other Grant/Funding Number: Norwegian Financial Mechanism )
First Posted: May 23, 2013    Key Record Dates
Last Update Posted: May 23, 2013
Last Verified: May 2013

Additional relevant MeSH terms:
Dermatitis
Dermatitis, Atopic
Eczema
Food Hypersensitivity
Respiratory Sounds
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms